The First Photograph of CB1 — Seeing the Brain's Cannabinoid Receptor at Atomic Resolution
Crystal Structure of the Human Cannabinoid Receptor CB1
In 2016, an international team of 23 researchers finally solved the 3D crystal structure of the human CB1 receptor at 2.8 angstrom resolution — 26 years after the gene was cloned — enabling scientists to see exactly how THC, endocannabinoids, and synthetic cannabinoids fit into the receptor's binding pocket.
For twenty-six years, the CB1 cannabinoid receptor existed as a sequence of letters — 472 amino acids, spelled out in a gene database. Scientists knew the parts list. They knew the receptor was the most abundant GPCR in the brain. They knew it bound THC, anandamide, and 2-AG. They knew its pharmacology in exhaustive detail.
But nobody had ever seen it.
Knowing a gene sequence without knowing the 3D structure is like having every ingredient in a recipe without knowing what the dish looks like. You can predict some things. You can't design a drug with precision. In October 2016, twenty-three researchers across seven institutions in three countries finally took the photograph.
Why It Took 26 Years
Solving a crystal structure sounds straightforward: purify the protein, grow crystals, shoot X-rays at them, compute the 3D shape from the diffraction pattern. In practice, for membrane proteins like GPCRs, every step is a nightmare.
CB1 is embedded in a cell membrane. Remove it from the membrane and it loses its shape. It's flexible — constantly shifting between conformations. It has seven transmembrane helices that need to be just right. And to grow a crystal, you need billions of identical protein molecules to stack into a perfect lattice. A protein that won't sit still won't crystallize.
By 2016, decades of GPCR crystallography had produced solutions to each problem — but each had to be adapted specifically for CB1:
The scale of the effort reflects how modern structural biology works. This wasn't one lab with one technique. It was a synthetic chemistry lab (Makriyannis, Northeastern) making the drug, a structural biology institute (iHuman, ShanghaiTech) growing crystals and solving the structure, a functional pharmacology lab (Bohn, Scripps) validating the biology, and a computational group (Kufareva, UCSD) modeling drug binding — all coordinated across continents.
23
authors from 7 institutions across 3 countries — a collaboration spanning synthetic chemistry (Boston), structural biology (Shanghai), functional pharmacology (La Jolla), and computational modeling (San Diego). Modern structural biology at this level requires an army.
For context: the THC isolation paper had 2 authors. The CB1 cloning paper had 5. The anandamide paper had 10. The crystal structure needed 23.
Hua et al. (2016), Cell
The Drug That Made the Picture Possible
The unsung hero of this paper is a molecule most people will never hear of: AM6538.
Alexandros Makriyannis, the George Behrakis Chair in Pharmaceutical Biotechnology at Northeastern University, has spent over four decades designing synthetic cannabinoids. Not recreational drugs — research tools. Molecules precisely engineered to bind cannabinoid receptors in specific ways, to serve as probes for understanding how the system works.
AM6538 was his masterpiece of purpose-built pharmacology. It's a CB1 antagonist — structurally related to rimonabant — but designed with a single goal: bind CB1 so tightly and so stably that the receptor would stop moving long enough to form a crystal. The drug isn't meant to be a medicine. It's meant to be a molecular splint.
It worked. AM6538 locked CB1 into a rigid inactive conformation. Crystals formed. X-rays scattered. For the first time in history, the 3D shape of the brain's cannabinoid receptor emerged from the data.
What the Structure Reveals
The structure revealed several features that couldn't be predicted from the sequence alone:
The binding pocket is deep and narrow — a long, tunnel-like cavity extending from the extracellular surface into the transmembrane core. THC slides in lengthwise, its tricyclic ring system making contacts with specific amino acids lining the tunnel walls. This geometry explains why small changes in cannabinoid structure (a pentyl chain vs a propyl chain, as in THC vs THCV) produce such different pharmacological profiles.
The antagonist-binding mode showed that AM6538 occupies the same tunnel but plugs it differently than agonists — blocking the conformational changes needed for receptor activation. This is the structural explanation for what Pertwee had characterized pharmacologically: antagonists don't just compete for the same site, they prevent the receptor from changing shape.
The structure also identified regions consistent with allosteric binding sites — locations away from the main pocket where modulators like CBD could bind and alter the receptor's response to THC without directly competing for the same spot. This structural feature directly supports the negative allosteric modulator model for CBD.
From Photograph to Drug Design
The crystal structure didn't just satisfy scientific curiosity. It launched a new era of cannabinoid drug development.
Before the structure: Drug design meant synthesizing hundreds of compounds, testing each one in cell assays or animals, and iterating. A single drug candidate might take years of trial and error.
After the structure: Computational chemists can dock millions of virtual molecules into the 3D binding pocket, score how well each fits, and select only the best candidates for actual synthesis and testing. This doesn't replace experiments — but it compresses years of screening into weeks of computing.
The practical applications include:
- Peripherally-restricted CB1 antagonists — using the structure to design molecules that block CB1 in the gut and liver (for metabolic disease) but can't cross the blood-brain barrier (avoiding rimonabant's psychiatric side effects)
- Biased agonists — molecules designed from the structure to activate therapeutic signaling pathways (pain relief) without activating pathways that produce psychoactivity or tolerance
- Allosteric modulators — compounds targeting sites identified in the structure that fine-tune receptor activity rather than fully activating or blocking it
The Arc From Molecule to Atom
This study completes a 52-year arc in cannabinoid science:
1964: Mechoulam identifies the THC molecule — the key.
1988-1990: Howlett proves a receptor exists, then Matsuda clones the gene — the lock.
1992-1997: Anandamide and 2-AG are found — the body's own keys.
2006-2008: Pacher maps the therapeutic landscape, Pertwee characterizes the pharmacology — understanding how the lock and keys interact.
2016: This paper — the first photograph of the lock, at atomic resolution.
Each step required the one before it. You can't photograph a receptor you haven't cloned. You can't clone a receptor you haven't proven exists. You can't prove a receptor exists without the molecule it responds to. Fifty-two years from organic chemistry to structural biology, each generation handing the next the tools it needed.
Frequently Asked Questions
Cite this study
Hua, T; Vemuri, K; Pu, M; Qu, L; Han, G W; Wu, Y; Zhao, S; Shui, W; Li, S; Korde, A; Laprairie, R B; Stahl, E L; Ho, J H; Zvonok, N; Zhou, H; Kufareva, I; Wu, B; Zhao, Q; Hanson, M A; Bohn, L M; Makriyannis, A; Stevens, R C; Liu, Z J. (2016). Crystal Structure of the Human Cannabinoid Receptor CB1. Cell, 167(3), 750-762.e14. https://doi.org/10.1016/j.cell.2016.10.004